All In Biotech

Drug Trial Radar · NCT00784225

S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000

S0000B: Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium - SELECT Eye Endpoints (SEE)

Last checked: Nov 20, 2026Latest source record: Aug 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 13,475 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

13,475

Actual

Start

Jul 2004

Primary completion

Nov 2017

Study completion May 2018

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); National Eye Institute (NEI)
First posted
Nov 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Male only, from 50 years, up to 120 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent cataracts or age-related macular degeneration in men receiving these drugs as part of a clinical trial for the prevention of prostate cancer. PURPOSE: This clinical trial is studying vitamin E and/or selenium to see how well they work in preventing cataract and age-related macular degeneration in men enrolled on SELECT (SWOG-S0000).

Conditions

  • Cataract
  • Macular Degeneration

Interventions

  • seleniumDrug

    200 mcg daily for 7-12 years

  • vitamin EDrug

    400 IU daily by mouth for 7-12 years

  • vitamin E placeboDrug

    daily for 7-12 years

  • selenium placeboDrug

    daily for 7-12 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Visually Significant Age-related Macular Degeneration (AMD)Time frame: Every 6 months, up to 7 years
  2. Number of Participants With Cataract and Best Corrected Visual-acuity of 20/30Time frame: Every 6 months, up to 7 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harvard Medical School

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.